Women's Health Initiative Sight Examination (WHISE)

This substudy phs000503 WHISE contains phenotypes only for the Sight Examination study. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page [phs000200](./study.cgi?study_id=phs000200) WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study [phs000200](./study.cgi?study_id=phs000200).

Women enrolled in the Women's Health Initiative (WHI) Hormone Replacement Therapy (HRT) Clinical Trial (CT) were included in this study. In WHI, participants who did not have a hysterectomy before enrollment into the WHI HRT CT were randomly assigned to either conjugated equine estrogens with progestin (CEE P) (0.625 mg/d of CEE and 2.5 mg/d of progestin) or a placebo. Those without a uterus were randomly assigned to either CEE (0.625 mg/d) or a placebo. Participants in the WHISE Study were recruited an average of 5.1 years after randomization into the WHI HRT CT. Participants included 4688 women who consented to participate in the WHISE Study; 4347 completed enrollment with photographs of at least 1 eye. The purpose of the study was to evaluate the effects of HRT on age-related macular degeneration.